Abstract
Background: Gemcitabine and vinorelbine are active agents for the treatment of metastatic breast cancer. Prolonged infusion of gemcitabine can result in higher levels of active metabolites compared to shorter administration. This phase II trial was initiated to evaluate the efficacy and tolerability of gemcitabine as prolonged infusion in combination with vinorelbine in anthracycline and/or taxane pretreated patients with metastatic breast cancer. Patients and methods: Patients who had received one prior line of chemotherapy for metastatic disease were treated with gemcitabine (350 mg/m2 as 4 h infusion) and vinorelbine (25 mg/m2) on days 1 and 8. Treatment was repeated every 3 weeks for a maximum of six cycles. Results: Of 26 patients enrolled, 84% had received prior anthracycline treatment and 50% prior taxane therapy. In total, one complete and six partial responses were achieved, accounting for an overall response rate of 30.4%. The clinical benefit rate was 47.8%. Median duration of response and median time to progression were 7.3 months and 4.6 months, respectively. Median overall survival was 14.5 months. Although the predominant toxicity was myelosuppression with grade 3/4 neutropenia in 42% of patients, few neutropenic complications resulted. Non-hematological toxicity was generally moderate. Most common non-hematologic toxicities were nausea, vomiting, alopecia, peripheral neuropathy and elevation of liver enzymes. Conclusion: Gemcitabine as prolonged infusion and vinorelbine are a safe and effective combination treatment in anthracycline and/or taxane pretreated patients. Approximately 47.8% of patients derived clinical benefit from treatment. This regimen represents a therapeutic option for patients receiving second-line therapy for metastatic breast cancer.
Similar content being viewed by others
References
Abbruzzese JL, Grunewald R, Weeks EA (1991) A phase I clinical, plasma, and cellular pharmacology study of gemcitabine. J Clin Oncol 9(3):491–498
Akrivakis K, Schmid P, Flath B, Schweigert M, Mergenthaler HG, Possinger K (1999) Prolonged infusion of gemcitabine in stage IV breast cancer: a phase-I-study. Anticancer Drugs 10(6):525–531
Binet S, Chaineau E, Fellous A, Lataste H, Krikorian A, Couzinier JP, Meninger V (1990) Immunofluorescence study of the action of navelbine, vincristine and vinblastine on mitotic axonal microtubules. Int J Cancer 46:262–266
Blackstein M, Vogel CL, Ambinder R, Cowan J, Iglesias J, Melemed A (2002) Gemcitabine as first-line therapy in patients with metastatic breast cancer: a phase II trial. Oncology 62:2–8
Brodowicz T, Kostler WJ, Moslinger R, Tomek S, Vaclavik I, Herscovici V, Wiltschke C, Steger GG, Wein W, Seifert M, Kubista E, Zielinski CC (2000) Single-agent gemcitabine as second- and third-line treatment in metastatic breast cancer. Breast 9:338–342
Bruno S, Puerto VL, Mickiewicz E, Hegg R, Texeira LC, Gaitan L, Martinez L, Fernandez O, Otero J, Kesselring G (1995) Phase II trial of weekly i.v. vinorelbine as a single agent in first-line advanced breast cancer. Am J Clin Oncol 18:392–396
Carmichael J, Possinger K, Phillip P, Beykirch M, Kerr H, Walling J, Harris AL (1995) Advanced breast cancer: a phase II trial with gemcitabine. J Clin Oncol 13(11):2731–2736
Degardin M, Bonneterre J, Hecquet B, Pion JM, Adenis A, Horner D, Demaille A (1994) Vinorelbine (Navelbine) as salvage treatment for advanced breast cancer. Ann Oncol 5:423–426
Donadio M, Ardine M, Berruti A, Ritorto G, Fea E, Mistrangelo M, Coccorullo Z, Bergnolo P, Comandone A, Bertetto O (2003) Gemcitabine and vinorelbine as second-line treatment in patients with metastatic breast cancer: a phase II study. Cancer Chemother Pharmacol 52(2):147–152
Feher O, Vodvarka P, Jassem J (2002) Randomized phase III study of epirubicin versus gemcitabine chemotherapy in elderly females with metastatic breast cancer. In: European Breast Cancer Conference, 110 p
Garcia-Conde J, Lluch A, Martin M, Casado A, Gervasio H, De Oliveira C, De Pablo JL, Gorostiaga J, Giron GC, Cervantes A (1994) Phase II trial of weekly i.v. vinorelbine in firstline advanced breast cancer chemotherapy. Ann Oncol 5:854–857
Gasparini G, Caffo O, Barni S, Frontini L, Testolin A, Guglielmi RB, Ambrosini G (1994) Vinorelbine is an active antiproliferative agent in pre-treated advanced breast cancer patient: a phase II study. J Clin Oncol 12:2094–2101
Gerson R, Serrano OA, Villalobos A, Ortiz C, Sanchez-Forgach R (2000) Gemcitabine response in advanced breast cancer in relation to immunohistochemical factors. Proc Am Soc Clin Oncol 19:572
Grunewald R, Abbruzzese JL, Tarassoff P, Plunkett W (1991) Saturation of 2’,2’-difluorodeoxycytidine 5’-triphosphate accumulation by mononuclear cells during a phase I trial of gemcitabine. Cancer Chemother Pharmacol 27(4):258–262
Haider K, Kornek GV, Kwasny W, Weinlander G, Valencak J, Lang F, Puribauer F, Kovats E, Depisch D, Scheithauer W (1999) Treatment of advanced breast cancer with gemcitabine and vinorelbine plus human granulocyte colony-stimulating factor. Breast Cancer Res Treat 55:203–211
Heinemann V, Schukz L, Issels RD, Plunkett W (1995) Gemcitabine: a modulator of intracellular nucleotide and deoxynucleotide metabolism. Semin Oncol 22(suppl 11):11–18
Huang P, Plunkett W (1995) Induction of apoptosis by gemcitabine. Semin Oncol 22(suppl 11):19–25
Kaye SB (1994) Gemcitabine current status of phase I and II trials. J Clin Oncol 12(8):1527–1531
Livingston RB, Ellis GK, Gralow JR, Williams MA, White R, McGuirt C, Adamkiewicz BB, Long CA (1997) Dose-intensive vinorelbine with concurrent granulocyte colony-stimulating factor support in paclitaxel-refractory metastatic breast cancer. J Clin Oncol 15:1395–1400
Mariani G, Tagliabue P, Zucchinelli P, Brambilla C, Demicheli R, Villa E, Marchiano A, Valagussa P, Bonadonna G, Gianni L (2001) Phase I/II study of gemcitabine in association with vinorelbine for metastatic breast cancer. Breast Cancer Res Treat 70(3):163–169
Maurel J, Zorrilla M, Puertolas T (2001) Phase I trial of weekly gemcitabine at 3-h infusion in refractory, heavily pretreated advanced solid tumors. Anticancer Drugs 12(9):713–717
Morabito A, Filippelli G, Palmeri S, Cascinu S, Ferrau F, Zagonel V, Gattuso D, Catalano V, Capaccetti B, Franciosi V, Accurso V, Scinto F, Gasparini G (2003) The combination of gemcitabine and vinorelbine is an active regimen as second-line therapy in patients with metastatic breast cancer pretreated with taxanes and/or anthracyclines: a phase I-II study. Breast Cancer Res Treat 78(1):29–36
Nicolaides C, Dimopoulos MA, Samantas E, Bafaloukos D, Kalofonos C, Fountzilas G, Razi E, Kosmidis P, Pavlidis N (2000) Gemcitabine and vinorelbine as second-line treatment in patients with metastatic breast cancer progressing after first-line taxane-based chemotherapy: a phase II study conducted by the Hellenic Cooperative Oncology Group. Ann Oncol 11:873–875
Plunkett W, Huang P, Xu YZ, Heinemann V, Grunewald R, Gandhi (1995) Gemcitabine: metabolism, mechanisms of action, and self-potentiation. Semin Oncol 22(suppl 11):3–10
Pollera CF, Ceribelli A, Crecco M (1997) Prolonged infusion of gemcitabine: a clinical phase I study at low-(300 mg/m2) and high-(875 mg/m2) levels. Invest New Drugs 15(2):115–121
Possinger K, Kaufmann M, Coleman R, Stuart NS, Helsing M, Ohnmacht U, Arning M (1999) Phase II study of gemcitabine as first-line chemotherapy in patients with advanced or metastatic breast cancer. Anticancer Drugs 10(2):155–162
Rossi E, Perrone F, Labonia V, Landi G, Nuzzo F, Amabile G, Gridelli C, Di Maio M, D’Aiuto G, de Matteis A (2003) Is gemcitabine plus vinorelbine active in second-line chemotherapy of metastatic breast cancer? a single-center phase 2 study. Oncology 64(4):479–480
Sanal SM, Gokmen E, Karabulut B, Sezgin C (2002) Gemcitabine and vinorelbine combination in patients with metastatic breast cancer. Breast J 8(3):171–176
Schmid P, Schweigert M, Beinert T, Flath B, Sezer O, Possinger K (2005) Prolonged infusion of gemcitabine in advanced solid tumors: a phase-I-study. Invest New Drugs 23:139–146
Smorenburg CH, Bontenbal M, Seynaeve C, van Zuylen C, de Heus G, Verweij J, de Wit R (2001) Phase II study of weekly gemcitabine in patients with metastatic breast cancer relapsing or failing both an anthracycline and a taxane. Breast Cancer Res Treat 66:83–87
Spielmann M, Llombart-Cussac A, Kalla S, Espie M, Namer M, Ferrero JM, Dieras V, Fumoleau P, Cuvier C, Perrocheau G, Ponzio A, Kayitalire L, Pouillart P (2001) Single agent gemcitabine is active in previously treated metastatic breast cancer. Oncology 60:303–307
Stathopoulos GP, Rigotos SK, Pergantas N, Tsavdarides D, Athanasiodia I, Malamos NA, Stothopoulos JG (2002) Phase II trial of biweekly administration of vinorelbine and gemcitabine in pretreated advanced breast cancer. J Clin Oncol 20:37–41
Tonato M, Mosconi AM, Martin C (1995) Safety profile of gemcitabine. Anticancer Drugs 6(suppl 6):27–32
Valenza R, Leonardi V, Gebbia V, Agostara B (2000) Gemcitabine and vinorelbine in pretreated advanced breast cancer: a pilot study. Ann Oncol 11:495–496
Valerio MR, Cicero G, Armata MG (2001) Gemcitabine in pretreated breast cancer. Proc Am Soc Clin Oncol 20:1953
Veerman G, Ruiz van Haperen VW, Vermorken JB (1996) Antitumor activity of prolonged as compared with bolus administration of 2’,2’-difluorodeoxycytidine in vivo against murine colon tumors. Cancer Chemother Pharmacol 38(4):335–342
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Schmid, P., Heilmann, V., Schulz, CO. et al. Gemcitabine as prolonged infusion and vinorelbine in anthracycline and/or taxane pretreated metastatic breast cancer: a phase II study. J Cancer Res Clin Oncol 131, 568–574 (2005). https://doi.org/10.1007/s00432-005-0675-y
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00432-005-0675-y